前苏联专利SU999966A3 Process for producing derivatives of imidazole or their salts

专利PDF首页>>前苏联专利

专利附录

专利说明

权利要求

类似技术

同族专利

引用文献

法律状态

优先权

专利摘要:
Novel imidazole-5-acetic acid derivatives of the formula: wherein R' is lower alkyl, cycloalkyl or, phenyl which may be substituted with one to three of halogen, nitro, amino, mono (lower alkyl) amino, di (lower alkyl) amino, lower alkyl, lower alkoxyl, benzyloxyl or/and hydroxyl; X1, X2 and X3 are each hydrogen, halogen, nitro, amino, lower alkyl, lower alkoxyl, benzyloxyl or hydroxyl; Y is halogen and R2 is hydrogen or lower alkyl; provided that X' is halogen, lower alkyl, lower alkoxyl, benzyloxyl or hydroxyl when R' is unsubstituted or substituted phenyl only with one halogen, di(lower alkyl) amino, lower alkyl or lower alkoxyl, and its salts have hypotensive activity
公开号:SU999966A3
申请号:SU803003450
申请日:1980-11-10
公开日:1983-02-23
发明作者:Фурукава Есиясу；Кисимото Содзи；Нисикава Кохей
申请人:Такеда Кемикал Индастриз (Фирма)；
IPC主号:

专利说明:

(54) THE METHOD OF OBTAINING IMIDAZOLE DERIVATIVES OR THEIR SLEP, lD-NHCHO, is subjected to alkaline or acid hydrolysis when R is hydrogen, or alcoholysis, when R is lower alkyl, to release the desired product in free form or as a salt. Example. 7 g of 1-benzyl-4-chloro-5-cyanomethyl-2- (4-nitrophenyl) imidazol is boiled in 60 ml of bn-hydrochloric acid for 4 hours. The reaction solution is diluted with 150 m of water and the precipitated precipitate is dissolved by heating in 50 ml of 90% ethanol. Water is gradually added until the appearance of turbidity, after which the solution is allowed to cool. 5.6 g of 1-benzyl-4chloro-2- (4-nitrophenyl) imidazole-5-acetic acid are obtained, precipitated in the form of yellow, prismatic crystals, m.p. leo-iea c. Found,%: C 58.29; H 3.77 / N 11.11; С-Е- 9.77 С 8Н 4Мг04Сб Calculated,%: С 58.15; H 3.79; N 11.30; Ct 9,54. Example2. 1.9 g of 1- (2-chloro-5-nitrobenzyl) -4-chloro-5-cyanomethyl-2-phenylimidazole is boiled in a mixed solution of 12 ml of concentrated hydrochloric acid and 12 ml of glacial - acetic acid for 3 hours. The reaction solution is then concentrated to dryness under reduced pressure, and 50 ml of water is added to the residue, which leads to a colorless powder. The residue was dissolved in 30 ml of heated ethanol and 30 ml of water was added. After cooling, 1.7 g of 1- (2-chloro-5-nitroben-, 3yl) -4-chloro-2-phenylimidazole-5-acetic acid are obtained in the form of colorless, prismatic crystals, m.p. 200-250 ° C. Found,%: C 53.32; H 3.03, N 10.44. Ct 17.44 N, 04Cei Calculated: C, 53.22; H, 3.23; N 10.34} CE 17.44. Froze 3.8 g of 1- (2,4-dichlorobenzyl} -4-chloro-2-phenyl-5-cyanomethylimidazole is boiled in 40 ml of n-hydrochloric acid for 11 hours. After cooling, the crystals precipitated from the solution are recrystallized from acetonitrile, thus obtaining 3.5 g of 1- (2,4-dichlorobenzyl) -4-chloro-2-phenylimidazole-5-acetic acid hydrochloride in the form of colorless, needle-like crystals, mp 209211 C. Found: C 48, 14 / H 3.50, 6.29; Ct 31.26. Cffl H f N2.02C f% HC 1: Calculated,%: C 48.02; H 3.58 / 6.22; Ct. 31.50 Both p and me r in 4-35. Using the techniques described in examples 1d-3, the following compounds wW are obtained The properties of which are presented in Table 1. T a b l and c a 1
i Continuation of tab. one
(
35 Example 36 1.7 g of 4-HLOR-1- (3-methoxybenzyl) -2-phenyl-5-cyanomethylimidazole are boiled in a mixture solution of 20 ml of ethanol and 10 ml of 1N. hydroxide, sodium for 10 hours. The reaction solution is evaporated to dryness under reduced pressure and the residue is dissolved in 50 ml of water. After washing with 50 ml of chloroform, 10 ml of 1N is added to the aqueous layer. hydrochloric acid, which leads to precipitation. The precipitate was dissolved in 20 MP of 90% ethanol, and water was gradually added, yielding 1.3 g of 4-chloro-1- (3-methoxybenzyl) -2-5-phenylimidazole-5-acetic acid as colorless , needle crystals, so pl. 135-13I C.
164-165 N N sv st
Table 2 Found,%: C 64.22; H 4.72; , 89; CE 9.91 SUO Y, 7 MAOLSV-. Calculated:.% I С 63.95; H-4.80, 85 / CE 9.93. Examples 37-49, According to the procedure of Example 36, the half-following compounds of which are listed in Table 2.
(dil; ii: Example Example 50 Methanol HUOmp is dissolved in 1.8 g of 4-chloro-1- (4-methylbenzyl) -2-phenylimidazole-5-acetic acid, and 0.5 ml of concentrated sulfuric acid is added to the solution. boil for 2 hours. The reaction solution is evaporated to a residue under reduced pressure and 50 ml of ethyl acetate and 50 ml of 10% aqueous sodium bicarbonate are added to the residue for shaking. After washing the solution in ethyl acetate, it is evaporated to dryness under reduced pressure. pressure. The residue is a solution in a small amount of methanol and after settling the floor 1.5 g of methyl 4-chloro-1- (4-methylbenzyl) -2-phenylimidazole-5-acetate are present in the form of colorless, prismatic crystals, mp 92 95 ° C. Found: C 67.34 , H 5.56; N 7.71; СЬ 9.61, .OaCt Calculated: C 67.70; H 5.39; N 7.89, CE 9.99. Example 51. 1 g 1-benzyl -2-n-butyl-4-chloro-5-cyanomethyl imidazole is heated in 20 ml of ethanol containing 1 g of hydrogen chloride in a sealed ampoule for 2 hours, 0.5 ml of water is added to the reaction solution, after they are boiled for 1 h and evaporated to dryness under reduced pressure .. The residue is dissolved in 50 ml of ethyl acetate and, after washing with an aqueous bi arbonatom sodium wicked The ethyl acetate was evaporated to dryness and
Continued table. g X, I X., 3-СНзО J Хз Тт. Square H 230-232 199-200 203-205 4-CH O 5-CH.jO 161-162 chromatographically in a column with 30 g of silica gel. The column was eluted with benzoglu-ethyl acetate (4: 1), and the main fractions were evaporated to dryness. The residue is dissolved in 1 ml of ethanol saturated with hydrogen chloride, and crystallized by the addition of petroleum ether. After additional addition of t-acetate to separate, in a fully crystalline state, ethyl acetate 1-benzyl-2-n-butyl-4-chlorimidazole-5-acetate. hydrochloride, so pl. 101-103 C. Found,%: C 57.02; H 6.42; N 7.40. С, о НлаМ „Оа, С1 - НСе 1/2 NgCalculated,% С 56.85, Н 6.62jN 7.36, Example52. 05 ml tetrahydro-. furan is dissolved in 1.5 g of 4-chloro-1- (2-fluorobenzene) -2-phenyl-5-formyl-imidazole, and the solution is stirred and heated to reflux. In 3 MP tetrahydrofur is dissolved in 1 ml of formaldehyde-dimethylthio-acetal-M-oxide and 35% of an anhydrous hydroxybeneyltrimethyl-ammonium solution for drip addition to the said solution for 2 h. After the addition is complete, the reaction solution is boiled. for another 5 hours and evaporated to dryness under reduced pressure. 50 ml of chloroform and water are added to the residue and shaken to mix, followed by evaporation of the chloroforane layer to a dry residue, to give a resin-like material 1-methylsulfinyl-1-methylthio-2- C (4-chloro-1-) - - - fluorobenzyl) -2-phenylimide sol-H) -yl ethylene. 5 jvin of concentrated hydrochloric acid and 5 ml of glacial acetic acid are added to the material and heated at 100 ° C for 5 hours. The reaction solution is evaporated to dryness under reduced pressure and 50 ml are added to the residue for shaking and mixing. ml of loroform and 10% aqueous solution of sodium carbonate. The aqueous layer is acidified by the addition of concentrated hydrochloric acid and extracted with 50 ml of chloroform. After evaporation of the chloroform layer to a dry residue under reduced pressure, recrystallization of the residue from aqueous ethanol gives 410 mg of 4-chloro-1- (2-fluorobenzyl) 2-phenylimidazole-5-acetic acid as colorless, prismatic crystals. M.p. 144-146 C. Found,%: C 62, 74; H 4.33 / N 7.87 C-J8 H 4N20zCtF Calculated: C 62.71, H 4.09, N 8.12. EXAMPLE 53 4.5 g of 4-chloro-1- (2 methylbenzyl) -2-phenyl-5-formyl-imidazole is dissolved in 30 ml of furan tetrahydrate and the solution is stirred and heated to reflux. In 30 ml of tetrahydro-furan, dilute with b ml of formaldehyde-dimethylthioe-acetal-M-oxide and b ml of 35% hydrochloride hydroxybenzylarymethyl-1-mono hydrochloride solution added dropwise to this solution during 12 hours. t for another 18 h and evaporated to a dry residue under reduced pressure. For shaking and transferring, 200 ml of chloroform and water are added to the residue, followed by evaporation of the chloroform layer to a dry residue, with the formation of a resin-like material 1-methylsulfinyl-1-methylthio-2- (4-chloro-1- (2- methylbenzyl-2-phenylimide sol-5-yl) ethylene. The material is dissolved in 100 ml of ethanol saturated with hydrogen chloride and allowed to stand at room temperature for 40 hours. The reaction solution is evaporated to a dry residue under reduced pressure and the residue is chromatographed 80 g of silica gel, followed by chlorine elution. The main fractions are collected to evaporate to dryness under reduced pressure. Recrystallization from methanol gives 1.5 g of methyl 4-chloro-1 (2-methylbenzyl) -2-phenylimidazole-5-acetate, mp 102- 105 C. Found,%; C 67.29, H 5.71; N 7.52 ", ce 9.58 N, j.OiCe B№1iclo,%: C 67.70, I 5.39, N 7 , 89, C1, 9.99. Example 54. 1.4 g of 1-Oenzyl-4-chloro-2- {4-dimethylamino-3, 5-dinitrophenyl) -5-cyanomethylimideol is mixed in 30 ml of concentrated hydrochloric acid at 70 ° C for 40 hours. The precipitated yellow crystals are isolated by filtration, washed twice with concentrated hydrochloride acid and a sufficient amount of water and recrystallized twice from 70% ethanol, thereby obtaining 0.9 g of 1-benzyl-4-chloro-2- (4-chloro-3, 5-dinitrophenyl) imidazole-5-acetic acid in as yellow-orange, needle-like crystals, m.p. 100-105 ° C. Found,%: C 48.28; H 3.56; N 11.36; Cb 14.15 C, 9 H 5L 40bCC; Calculated,%: C 48.25; H W, 65; N 11 /, 26; Ct 14.24. Example 55 1.7 g of benzyl-4-chloro-2- (4-n-butyrylaminophenyl) -5-cyan tilimidazole are mixed in a mixed solution of 9 ml of concentrated hydrochloric acid, p ml of water and 9 ml of glacial acetic acid at 120 ° for 5 hours, the reaction solution is evaporated to dryness under reduced pressure, and the residue is dissolved in 20 ml of water, followed by adjusting to pH 5 with sodium bicarbonate. The precipitated precipitate is recrystallized from 80% ethanol, thereby obtaining 1.3 g of 1-benz1-4-chloro-2- (4-aminophenyl) imidazole-5-acetic acid in the whole colorless needle-like crystals, m, pl. 120-122C. Found%: C 60.00, H 5.05 / N 11.76; C 9.66 CjQ NjOsrCe HaO Calculated. %: C 60.09, H 5.04; N 11.66; C 9.85 Example 56. 1.8 g of 1-benzyl-4chloro-2- (2-nitrophenyl) imidazole-5-acetic acid are dissolved in 100 ml of 80% ethanol and hydrogenated with B in the presence of 0.3 g of 10% palladium on coal The catalyst is filtered off and the filtrate, after adding 5 ml of 1N hydrochloric acid, is evaporated to dryness under reduced pressure, which leads to 1.3 g of 1-benzyl-4-utor-2- (2-aminophenyl) -imidazole-5-acetic acid hydrochloride in the form of a colorless powder, m.p. 115-120 ° C. Found,%: C 56.85, H 4.66 / N 10.97; Ci 18.66. C gH gNjOaCI .HCl Calculated,%: C 57.15; H 4.53; N 11.11; every 18.74. Example 57 2.8 g of 1-benzyl 4 -clav-2- (4-benzyloxy-3-methoxyphenyl-5-cyanomethylimidazole) is boiled in
smssevom solution 45 ml 6 n. hydrochloric acid and 10 ml of glacial acetic acid for 3., 5 hours. The reaction solution is evaporated to dryness under reduced pressure and the residue is dissolved in 30 ml of water. After the solution is adjusted to pH 3 with sodium bicarbonate, 2 g of 1-benz1-4-chloro-2- (4-hydroxy-3-methoxyphenyl) imidazole-5-acetic acid are precipitated as colorless prismatic crystals, which are isolated by filtration, T.hii . P9-181. ° C,
Found%: C 61.06, H 4.51} N 7.56
H N2.04.C6.
Calculated%: C 61, H 4.60; N 7.51.
Example 58. 1 g of 1-benzyl-4-chloro-2- (4-n-butoxyphenyl) imidazole-5-acetic acid is boiled in 14 ml of 48% hydrobromic acid for 2 hours, and adding 15 ml of water followed by leaving the solution to settle leads to precipitation of crystals. Recrystallization of crystals from aqueous ethanol gives 0.5 g of 1-benzyl-4-chloro-2- (4-hydroxyphenyl) imidazole-5-acetic acid as colorless prismatic crystals m.p. 140-145C. , G. VI i Example
Found,%: C 62.76; H 4.61; 8.0i; C & 9.77
C gHYs-NgOaCe
Calculated,%: C 63.10; H 4.38, 8.17; From 10.34.
Example59. 1 g of l-benzyl-4-chlorop-2- (3-methoxyphenyl) -imidazole-5-acetic acid is boiled in 14 ml. 48% hydrobromic acid for 2 hours. The reaction solution is evaporated to a dry residue, and after adding water to the residue, a white powder precipitates. The powder was dissolved in 10 ml of hot ethanol, and water was added to the solution until turbidity appeared. After one hundred percent, 0.8 g of 1-benz1-1-chloro-2- (3-hydroxyphenyl) imidazole-5-acetic acid is obtained in the form of colorless prism crystals t.15l. 220-222®C. Found,%: C 63.19; H 4.20; N 8.04; St. 10.18,
Q9 u
Calculated,%: C 63.10; H 4.38, N 8.17; every 10.34.
Examples 60-62. In accordance with the procedures of Examples 58 and 59, the following compounds are obtained, the properties of which are presented in table 3.,
Table I 3 il m.p.
60
61
62
175-178
H
153-155
197-199
Example 63 1.3 g of 1- {4-benzyloxybenzyl) -4-chlorop-2-phenylimidazol-5-ycyclic acid are boiled in 50 ml of ethanol saturated with hydrogen chloride for 7 hours. The reaction solution is evaporated to a dry residue at 50 ml of 5% aqueous solution of sodium carbonate and ethyl acetate are added to the residue for shaking. The ethyl acetate layer is washed and evaporated to dryness under reduced pressure. Recrystallization of the residue from 10 ml of acetonitrile gives 140 mg of 1- (4-hydroxybenzyl) -4-chloro-2-phenylimidazole-5-acetic acid as colorless crystals, m.p. 196-199C.
Found,%: C 64.95 N 5.28} cr
ClooH Q-NaOsCl
Calculated,%: C 64.77; N 5.16, se 7.56.
Example 64. In 5 ml of ethanol, 680 Mg of 4-chloro-2-phenyl-1- (4-methyl-benzyl) imidazole-5-acetic acid is dissolved and a solution of 80 mg of sodium hydroxide in 1 ml is added to the solution
water. The mixture solution was evaporated to dryness under reduced pressure and the residue was dissolved in 5 ml of ethanol. After adding 30 ml of diethyl ether to the solution,
0.5 g of the sodium salt of the indicated compound as a colorless crystalline powder, m.p. 287-29SR
Example 65. To a solution of b g of 1,3-dithian in 66 ml of tetrahydrofuran, n-butyl lithium in 30 mg of hexane (1.6 m) is added dropwise under nitrogen and with cooling () for 15 minutes. After stirring the reaction mixture for 2 hours, while cooling, 13.6 1-benyl-4-chloro-5-formyl-2- (4-nitrophenyl) -imidaeol in 215 ml of tetrahydrofuran was added during 1 hour and then stirred for 20 hours while cooling on ice. The reaction mixture is / evaporated to dryness under reduced pressure and 200 ml of chloroform is added to the resulting residue, washed with 5% hydrochloric acid, water and saturated aqueous NaCl solution in the indicated order. The solution is dried over sodium sulfate and evaporated to dryness under reduced pressure, and the residue is dissolved in 200 ml of benzene and heated to boiling for 30 minutes after the addition of 1.6 g of M-toluene-sulphonic acid using a water separator to trap the receiving water. The reaction mixture is washed with 5% sodium bicarbonate, water and a saturated aqueous solution of NaC in this order and evaporated to a dry residue under reduced pressure. The resulting residue (20 g) of 2 (1-benzyl-4-chloro-2-) 4-nitrophenyl (imidazol-5-yl methylidene) -1,3-dictienum is heated to 210 ml under reflux for two hours. acetic anhydride and 70 ml of concentrated hydrochloric acid and concentrated to a dry residue under reduced pressure. The residue is dissolved in 200 ml of chloroform and washed with water, and then extracted twice with 200 ml of Is.NaOH.,
The combined extract was washed with chloroform and adjusted to pH with hydrochloric acid, and then extracted twice with 100 ml of chloroform. The chloroform layer is washed with water and concentrated to a dry residue under reduced pressure. The residue is recrystallized twice from 80% ethanol to obtain. 1.2 g of 1-benzyl-4-chloro-2- (4-nitrophenyl) imidazole-5-acetic acid in
ABOUT
4-С Н О3-СНд Н
69
as prismatic crystals, so pl. 180-183 p.
Example 66. 975 mg of potassium is dissolved in 35 ml of tert-butanol and concentrated to dryness under reduced pressure. The resulting residue is dissolved in 25 ml of DMSO and 0.5 ml of tert-butanol. The solution is added to a DMSO solution of 2/92 g of p-toluenesulfonylmethyl isocyanite and 1.7 g of 1- (4-x-Lorbenzyl) - -chloro-5-formyl-2-phenylimidazole while cooling on ice, and then stirred for
1h while cooling on ice and 18 hours at room temperature. The reaction mixture is poured into 150 ml of water and extracted three times with 100 ml portions of diethyl ether. The combined ethereal layer is treated with water.
and concentrated to dryness under reduced pressure, the resulting residue is chromatographed on C-0 g of silica gel and eluted with chloroform. The main fraction is concentrated to dryness under reduced pressure and the residue (0.3 g) of 1-formylamino-1-P-toluenesulfonyl-2- (1- (4-chlorobenyl) -4-chloro-2-phenylimidazol-5-yl) ethylene is heated to reflux for 2 hours in 2 ml of glacial acetic acid and
2 ml of concentrated hydrochloric acid. The reaction mixture is concentrated to dryness under reduced pressure, and the resulting residue is recrystallized.
from 5 ml of 60% ethanol to obtain 0.2 g of 1- (4-chlorobenzyl) -4-chloro-2-vonimidrodazol-5-acetic acid as colorless needles, mp. 203-205 ° С (with decomposition).
Pr and measures 67. 3.8 g of 4-chloro-1- (3-methyl-4-methoxybenzyl) -2-phenylimidazole-3-acetic acid are dissolved in 10.8 ml of 1N. sodium hydroxide when heated and the solution is concentrated to dryness under reduced pressure. The resulting residue is dissolved in 20 ml of acetone and triturated with diethyl ether to precipitate 4 g of the sodium salt of the indicated compound as colorless needles, mp. 272274 with (with decomposition).
Examples .68-74. In accordance with the procedures of Examples 1-67, the following compounds are obtained, the properties of which are shown in Table 1. four.
Table4
188-189 b according to the methods of example: 1-74 the following compounds can be synthesized: 2-butyl-4-chloro-1- (2-methoxybenzyl) imidazole-5-acetic acid, 2-isobutyl-4-chloro-1- (2-Chloroenzyl) imidazole-5-acetic acid, 2-butyl-4-chloro-1- (2-ethoxybenzyl) imidazole-5-acetic acid, 2-butyl-4-chloro-1- (2-proxybenzyl) imidazole -5-acetic acid, 2-butyl-4-chloro-1- (2-butoxybenz1) imidazap-5-acetic acid, 2-butyl-4-chloro-1- (2-bromobenzyl) imidazole-5-acetic acid and 2-phenyl-4-brs 1-1- (2-methoxybenzyl Thymidazole-5-acetic acid. Example 75. In cases where compound (I) According to the invention, it is used as a drug for treating severe hypertension, it is used, for example, in the following composition I. Tablets. 1) 1-Benzyl-2-H-butyl-4-chlorimide 3-acetic acid 10 mg 2) Lactose 35 mg 3); Corn starch 150 mg 4) Microcrystalline cellulose 30 mg 5) Magnesium stearate 5 mg A total of 1 tablet 230 mg 1), 2), 3) and two thirds 4) is mixed with half 5) and granulated. The remaining amount of 4) and 5) is added to the granules and pressed into tablets. Ii. Capsules 1) 1 - (4-ethoxybenzene1) -2-fennl-5-chlorimidazole-5-acetic acid 10 mg 2) Lactose90 mg
Continued table. 4 3) Microcrystalline cellulose 70 mg 4) Magnesium stearate 10 mg Total for 1 capsule: 1 mg, 2; and 3) mixed with a quarter 4) and granulated. The remaining 4) is added to the granules and the mixture is used to fill the gelatin capsule. til. Injection. 1) 1- (4-methylbenznl) -2-phenyb-B-chlorimidazole-5-sodium acetate 10 mg 2) Inositol (insulin) 100 mg 3) Ben; alcohol 20 mg Total for 1 capsule: 130 mg 1), 2) iZ) is dissolved in distilled water for injection to obtain 2 ml of solution and used for; fill ampoules. The whole preparative process is carried out under sterile conditions. Test Example 1. Antagonistic effect of the compound | (l) corAacHo of the invention in relation to angiotensin II (hereinafter M) on the aorta, rabbits. The preparation of blood vessels and the reaction is carried out in accordance with a known technique. When using A and at a concentration of 4 x X 10 M, the inhibitory activity is calculated using the following equation, based on the changes in the isometric voltage of the blood vessel caused by the action A AND I, as compared to the same value after the treatment with the drug for 15 minutes, respectively.
21
22
999966
11 | continued tab. five
H
H
H
H
H
H
H
- -СЛН-О / 4 9
{3 -C HjCIi O
U-3-sn o
-five
ten
I
51 73
f
ten
-g
86
ten
-82
ten
-t
ten
25
-S
ten
55 33 18
ten
-6
ten
, -6
IP
34 23
-6
ten
ten
16 42
, -6
ten
H N N
-S
73 61 43 41
ten
ten
-6
ten
-6
ten
1-6
56 19 38
ten
H
g5
YN
-6
10 Test Example 2. Inhibitory The activity of compound (I) according to the invention in relation to 65
Continued table. five
80 81 18 32
54 18
38
., 36
41
55
75
thirty
99
53
22
ten
65
57
84
10U, 100
34 18
. 85 A II induced blood pressure in rats. Rats — male breeds weighing 250–350 g by pentobarbital-sodium anesthesia (50 mg / kg intraperitoneal), are used to introduce cannulas into the tracheal, carotid and femoral arteries. To maintain anesthesia, pentobarbital dissolved in physiological saline is continuously infused intravenously (350 µg / kg / min). One hour after the operation, when the blood pressure becomes stable, A II is administered by continuous intravenous infusion of 20 ng / kg / min. After 30-60 minutes, stable blood pressure is reached. The increase in blood pressure after infusion of A II compared to the pressure before infusion was 45.5-2.1 mm Hg. (for 75 cases) Then the test drug substance (dissolved in 500 μl, fiei

权利要求:
Claims (1)
[1]
Invention Formula
Method for preparing imidazole derivatives of general formula I
“V.
CHfd
CMj
and: in which R is unsubstituted feil, phenyl, substituted by one to three substituents selected from the group of chlorine, bromine, nitro, aminomono (lower glykyl) amino, di (lower alkyl) amino, : lower alkyl, lower alkoxyl, hydroxybenzyl, and / or hydroxy group, gshyl cyclohexyl,} C, X, X) each is hydrogen, halogen / nitro, amino, lower alkyl, lower alkoxy, benzyloxy or natural salt solution / 100 g of body weight is administered intravenously to measure blood pressure after 10, 30 and 90 minutes. The inhibitory activity provided by the drug is calculated using the following equation: inhibitory activity,% X 100, where P. is a decrease in blood pressure after the administration of a drug (mm-Hg), Pg is an increase in blood pressure due to And II (mm Hg). The test results are given in Table. 6 T a b l and c 6 2799996 hydroxyl, R is hydrogen or lower alkyl, with the proviso that X is halogen, lower alkyl, lower alkoxyl, benoyloxy or hydroxyl, and R is unsubstituted phenyl or, substituted by just one,, " . -6 by the host, Bfcj6paHHf, tM of the soil, including chlorine, bromine, whether (lower alkyl) amino group, lower alkyl, or lower alkoxy, or its (.-Oli, which means that the compound of formula II O

类似技术:

公开号 | 公开日 | 专利标题

SU999966A3|1983-02-23|Process for producing derivatives of imidazole or their salts

SU1277894A3|1986-12-15|Method of producing 3-|indoles or their pharmaceutically acceptable acid-additive salts

US4169157A|1979-09-25|Therapeutic preparations for peptic ulcers comprising aliphatic ketone derivative

WO1985003076A1|1985-07-18|Dihydropyridazinones

WO2008040995A1|2008-04-10|Indazoles for use as dpp-iv inhibitors

CN103517896A|2014-01-15|Quinolinone derivatives

US4782055A|1988-11-01|Imidazopyridine compounds useful in the treatment of ulcers

IE56836B1|1992-01-01|Novel pharmaceutically active 1,2,3,4,4a,5,10,10a-octahydrobenzo|quinoline derivatives

US3178348A|1965-04-13|Hypotensive quinolines

US4048182A|1977-09-13|Derivatives of imidazo [4,5-b]pyridines

US5330989A|1994-07-19|Heterocycles substituted with biphenyl-3-cyclobutene-1,2-dione derivatives

EP0353198B1|1994-02-02|Parabanic acid derivatives and pharmaceutical compositions containing them

CS262690B2|1989-03-14|Process for preparing 1-/hydroxystyryl/-5h-2,3-benzodiazepines

KR840001131B1|1984-08-09|Process for preparing substituted -oxo- -phenyl-carbamoyl-pyrrol propionitriles

SU1033003A3|1983-07-30|Process for preparing derivatives of 4-pyrimidone or their pharmaceutically acceptable acid addition salts

IE44588B1|1982-01-27|Trans-4-heterocyclyl-3,4-dihidro-2h-benzo|pyran-3-ol esters

HU207047B|1993-03-01|Process for producing new pyridine derivatives and pharmaceutical copositions comprising same

EP0118564B1|1987-04-22|4-amino-tetrahydro-2-naphthoic acid derivatives

US3914236A|1975-10-21|1-|-isoquinolines and process for preparing them

WO1988001270A1|1988-02-25|Pyridopyrimidinediones

GB2193210A|1988-02-03|Glycine derivatives

KR980008230A|1998-04-30|Use of theophylline derivatives for the treatment and prevention of shock conditions, xanthine compounds and preparation methods thereof

JP2003055344A|2003-02-26|3,7-disubstituted indole derivative and medicinal composition including the same

US2874156A|1959-02-17|Substituted l

SU1433411A3|1988-10-23|Method of producing derivatives of 2-|-quinolon or pharmaceutically acceptable salts thereof

同族专利:

公开号 | 公开日

NO803388L|1981-05-13|

ES496709A0|1982-05-01|

EP0028834B1|1984-01-18|

DE3066205D1|1984-02-23|

AR228957A1|1983-05-13|

CA1152516A|1983-08-23|

US4355040A|1982-10-19|

NO151966B|1985-04-01|

PT72049B|1981-09-24|

JPS5671074A|1981-06-13|

ES8204724A1|1982-05-01|

GR72124B|1983-09-16|

AT5880T|1984-02-15|

EP0028834A1|1981-05-20|

NO151966C|1985-07-10|

DK478980A|1981-05-13|

NZ195517A|1982-12-07|

HU185389B|1985-01-28|

ZA806832B|1981-10-28|

FI803508L|1981-05-13|

IL61359D0|1980-12-31|

PT72049A|1980-12-01|

AU6412280A|1981-05-21|

JPS6364428B2|1988-12-12|

引用文献:

公开号 | 申请日 | 公开日 | 申请人 | 专利标题

CH510394A|1969-07-04|1971-07-31|Ciba Geigy Ag|Acaricidal agent|

CA1066709A|1975-03-10|1979-11-20|Walter A.M. Helsen|Preparation of loweralkyl imidazole carboxylates|

JPS611022B2|1978-05-15|1986-01-13|Takeda Chemical Industries Ltd|

JPS62529B2|1985-06-03|1987-01-08|Hitachi Ltd|CA1181082A|1981-11-20|1985-01-15|Toni Dockner|Substituted benzylimidazolium salts and microbicidescontaining these compounds|

IE56381B1|1982-12-20|1991-07-17|Merck & Co Inc|5-imidazoles|

US4602093A|1984-02-08|1986-07-22|Merck & Co., Inc.|Novel substituted imidazoles, their preparation and use|

US5036048A|1986-03-07|1991-07-30|Schering Corporation|Angiotensin II receptor blockers as antiglaucoma agents|

US5182264A|1986-03-07|1993-01-26|Schering Corporation|Angiotensin II receptor blockers as antiglaucoma agents|

US5354867A|1988-12-06|1994-10-11|E. I. Du Pont De Nemours And Company|Angiotensin II receptor blocking imidazoles|

US5210079A|1988-01-07|1993-05-11|E. I. Du Pont De Nemours And Company|Treatment of chronic renal failure with imidazole angiotensin-II receptor antagonists|

CA1334092C|1986-07-11|1995-01-24|David John Carini|Angiotensin ii receptor blocking imidazoles|

CA1338238C|1988-01-07|1996-04-09|David John Carini|Angiotensin ii receptor blocking imidazoles and combinations thereof with diuretics and nsaids|

EP0733366B1|1988-01-07|1998-04-01|E.I. Du Pont De Nemours And Company|Pharmaceutical compositions comprising angiotensin II receptor blocking imidazoles and diuretics|

US5138069A|1986-07-11|1992-08-11|E. I. Du Pont De Nemours And Company|Angiotensin II receptor blocking imidazoles|

NZ221427A|1986-08-18|1990-12-21|Smithkline Beckman Corp|2-mercaptoimidazole derivatives and pharmaceutical compositions|

US4820843A|1987-05-22|1989-04-11|E. I. Du Pont De Nemours And Company|Tetrazole intermediates to antihypertensive compounds|

US5189048A|1988-01-07|1993-02-23|E. I. Du Pont De Nemours And Company|Substituted 1,2,3 triazole angiotensin II antagonists|

US5015651A|1988-01-07|1991-05-14|E. I. Du Pont De Nemours And Company|Treatment of hypertension with 1,2,4-angiotensin II antagonists|

US5081127A|1988-01-07|1992-01-14|E. I. Du Pont De Nemours And Company|Substituted 1,2,3-triazole angiotensin II antagonists|

US4880804A|1988-01-07|1989-11-14|E. I. Du Pont De Nemours And Company|Angiotensin II receptor blocking benzimidazoles|

US5315013A|1988-01-07|1994-05-24|E. I. Du Pont De Nemours And Company|Substituted pyrazole angiotensin II antagonists|

US4916129A|1989-01-19|1990-04-10|E. I. Du Pont De Nemours And Company|Combination β-blocking/angiotensin II blocking antihypertensives|

CA2016710A1|1989-05-15|1990-11-15|Prasun K. Chakravarty|Substituted benzimidazoles as angiotensin ii antagonists|

US5064825A|1989-06-01|1991-11-12|Merck & Co., Inc.|Angiotensin ii antagonists|

US5185351A|1989-06-14|1993-02-09|Smithkline Beecham Corporation|Imidazolyl-alkenoic acids useful as angiotensin II receptor antagonists|

US5312828A|1989-06-14|1994-05-17|Finkelstein Joseph A|Substituted imidazoles having angiotensin II receptor blocking activity|

ES2142789T3|1989-06-14|2000-05-01|Smithkline Beecham Corp|IMIDAZOLYL-ALKENOIC ACIDS.|

EP0403158A3|1989-06-14|1991-12-18|Smithkline Beecham Corporation|Imidazolyl-alkenoic acids|

US5418250A|1989-06-14|1995-05-23|Smithkline Beecham Corporation|Imidazolyl-alkenoic acids useful as angiotensin II receptor antagonists|

EP0479892A1|1989-06-30|1992-04-15|E.I. Du Pont De Nemours And Company|Fused-ring aryl substituted imidazoles|

US5164407A|1989-07-03|1992-11-17|Merck & Co., Inc.|Substituted imidazo-fused 5-membered ring heterocycles and their use as angiotensin ii antagonsists|

DE69013607T2|1989-08-02|1995-03-02|Takeda Chemical Industries Ltd|Pyrazole derivatives, process for their preparation and use.|

US5250554A|1989-10-24|1993-10-05|Takeda Chemical Industries, Ltd.|Benzimidazole derivatives useful as angiotensin II inhibitors|

IL95975A|1989-10-24|1997-06-10|Takeda Chemical Industries Ltd|N-benzyl- 2-alkylbenzimidazole derivatives, their production and pharmaceutical compositions containing them|

US5177096A|1989-10-25|1993-01-05|Smithkline Beecham Corporation|Substituted 5-alkenyl)imidazoles and pharmaceutical methods of use thereof|

CA2028925A1|1989-11-06|1991-05-07|Gerald R. Girard|Substituted n-alkyl alanine derivatives|

US5248689A|1989-11-06|1993-09-28|Smithkline Beecham Corporation|Substituted N-alkyl alanine derivatives|

US5073566A|1989-11-30|1991-12-17|Eli Lilly And Company|Angiotensin ii antagonist 1,3-imidazoles and use thereas|

US5234917A|1989-12-29|1993-08-10|Finkelstein Joseph A|Substituted 5-carboxamide imidazoles|

ZA9010460B|1989-12-29|1992-11-25|Univ Technologies Int|Methods for modelling tertiary structures of biologically active ligands including agonists and antagonists thereto and novel synthetic antagonists based on angiotensin|

EP0557276A1|1989-12-29|1993-09-01|University Technologies International Inc. |Methods for modelling tertiary structures of biologically active ligands including agonists and antagonists thereto and novel synthetic antagonists based on angiotensin|

JPH0396182U|1990-01-19|1991-10-01|

US5011851A|1990-02-13|1991-04-30|Bristol-Myers Squibb Co.|Imidazole carboxylic acids and esters and inhibition of blood platelet aggregation therewith|

EP0442448A3|1990-02-13|1992-08-12|Bristol-Myers Squibb Company|Heterocyclic carboxylic acids and esters|

DE69129998T2|1990-02-15|1998-12-24|Takeda Chemical Industries Ltd|Pyrimidinedione derivatives, their preparation and use|

DE122010000024I1|1990-02-19|2010-07-08|Novartis Ag|acyl compounds|

CA2037630C|1990-03-07|2001-07-03|Akira Morimoto|Nitrogen-containing heterocylic compounds, their production and use|

US5270317A|1990-03-20|1993-12-14|Elf Sanofi|N-substituted heterocyclic derivatives, their preparation and the pharmaceutical compositions in which they are present|

DE4010797A1|1990-04-04|1991-10-10|Hoechst Ag|SUBSTITUTED AZOLES, METHOD FOR THE PRODUCTION THEREOF, MEANS CONTAINING THEM AND THE USE THEREOF|

US6004989A|1990-04-27|1999-12-21|Takeda Chemical Industries, Ltd.|Benzimidazole derivatives, their production and use|

US5703110A|1990-04-27|1997-12-30|Takeda Chemical Industries, Ltd.|Benzimidazole derivatives, their production and use|

US5196444A|1990-04-27|1993-03-23|Takeda Chemical Industries, Ltd.|1-ethyl 2-ethoxy-1-[[2'-biphenyl-4-yl]methyl]benzimidazole-7-carboxylate and compositions and methods of pharmaceutical use thereof|

ZA912983B|1990-04-27|1992-01-29|Takeda Chemical Industries Ltd|Benzimidazole derivatives,their production and use|

RU2147875C1|1990-05-11|2000-04-27|Пфайзер Инк.|Method and composition for reducing arterial blood pressure and treating the cases of congestive heart failure in mammals|

US5821232A|1990-05-11|1998-10-13|Pfizer Inc.|Synergistic therapeutic compositions and methods|

NZ238688A|1990-06-28|1992-05-26|Smithkline Beecham Corp|Substituted histidines: pharmaceutical compositions, preparation and uses thereof|

NZ239161A|1990-07-31|1994-01-26|Smithkline Beecham Corp|Substituted [1h-imidazol-5-yl] alkanoic acid derivatives; medicaments,|

FR2665702B1|1990-08-08|1994-02-25|Sanofi|N-SUBSTITUTED HETEROCYCLIC DERIVATIVES, THEIR PREPARATION, THE PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME.|

US5126342A|1990-10-01|1992-06-30|Merck & Co., Inc.|Imidazole angiotensin ii antagonists incorporating acidic functional groups|

AU636066B2|1990-10-30|1993-04-08|Takeda Chemical Industries Ltd.|Thienoimidazole derivatives, their production and use|

US5374615A|1990-10-31|1994-12-20|E. R. Squibb & Sons, Inc.|Indole- and benzimidazole-substituted imidazole and benzimidazole derivatives|

DE4036706A1|1990-11-17|1992-05-21|Hoechst Ag|METHOD FOR THE TREATMENT OF CARDIALS AND VASCULAR HYPERTROPHY AND HYPERPLASIA|

TW197428B|1991-01-04|1993-01-01|Hoechst Ag|

CA2058198A1|1991-01-04|1992-07-05|Adalbert Wagner|Azole derivatives, process for their preparation, and their use|

US5153347A|1991-01-31|1992-10-06|E. R. Squibb & Sons, Inc.|Phosphonate, phosphinate derivatives useful as antihypertensive agents|

US5616599A|1991-02-21|1997-04-01|Sankyo Company, Limited|Angiotensin II antagosist 1-biphenylmethylimidazole compounds and their therapeutic use|

CA2061607C|1991-02-21|1999-01-19|Hiroaki Yanagisawa|1-biphenylimidazole derivatives, their preparation and their therapeutic use|

US5104877A|1991-02-25|1992-04-14|Abbott Laboratories|Psoriasis treatment|

US5191086A|1991-03-19|1993-03-02|E.R. Squibb & Sons, Inc.|Imidazole and benzimidazole derivatives|

US5177074A|1991-03-26|1993-01-05|Merck & Co., Inc.|Angiotensin ii antagonists incorporating a substituted thiophene or furan|

TW274551B|1991-04-16|1996-04-21|Takeda Pharm Industry Co Ltd|

US5190942A|1991-04-22|1993-03-02|E. R. Squibb & Sons, Inc.|Benzoxazole and related heterocyclic substituted imidazole and benzimidazole derivatives|

GB9110635D0|1991-05-16|1991-07-03|Glaxo Group Ltd|Chemical compounds|

GB9110636D0|1991-05-16|1991-07-03|Glaxo Group Ltd|Chemical compounds|

US5332820A|1991-05-20|1994-07-26|E. I. Du Pont De Nemours And Company|Dibenzobicyclo octane angiotensin II antagonists|

IL102183A|1991-06-27|1999-11-30|Takeda Chemical Industries Ltd|Biphenyl substituted heterocyclic compounds their production and pharmaceutical compositions comprising them|

US5177097A|1991-07-24|1993-01-05|E. R. Squibb & Sons, Inc.|Acyl amidine and acyl, guanidine substituted biphenyl derivatives|

US5389661A|1991-12-05|1995-02-14|Warner-Lambert Company|Imidazole and 1,2,4-triazole derivatives with angiotensin II antagonist properties|

US5322950A|1991-12-05|1994-06-21|Warner-Lambert Company|Imidazole with angiotensin II antagonist properties|

US5212177A|1991-12-16|1993-05-18|E. R. Squibb & Sons, Inc.|Indole and benzimidazole-substituted dihydropyrimidine derivatives|

TW215434B|1992-03-07|1993-11-01|Hoechst Ag|

US5208234A|1992-03-10|1993-05-04|E. R. Squibb & Sons, Inc.|Substituted imidazole phosphonic and phosphinic acid derivatives|

DE4208052A1|1992-03-13|1993-09-16|Bayer Ag|IMIDAZOLYL SUBSTITUTED PHENYL ACIDANCE AMIDE|

DE4208051A1|1992-03-13|1993-09-16|Bayer Ag|SUBSTITUTED PHENYL ACIDIC ACID AMIDE|

US5616591A|1992-03-27|1997-04-01|E.R. Squibb & Sons, Inc.|Indole- and benzimidazole-substituted quinoline derivatives|

US5294722A|1992-04-16|1994-03-15|E. R. Squibb & Sons, Inc.|Process for the preparation of imidazoles useful in angiotensin II antagonism|

DE4212796A1|1992-04-16|1993-10-21|Bayer Ag|Propenoyl-imidazole derivatives|

US5380719A|1992-04-28|1995-01-10|E. R. Squibb & Sons, Inc.|Quinoxaline biphenyl angiotensin II inhibitors|

US5612360A|1992-06-03|1997-03-18|Eli Lilly And Company|Angiotensin II antagonists|

US5401851A|1992-06-03|1995-03-28|Eli Lilly And Company|Angiotensin II antagonists|

DE4220983A1|1992-06-26|1994-01-05|Bayer Ag|Imidazolyl-substituted phenylpropionic and cinnamic acid derivatives|

DE4221009A1|1992-06-26|1994-01-05|Bayer Ag|Imidazolyl-substituted cyclohexane derivatives|

RU2103262C1|1992-07-16|1998-01-27|Лонца АГ Гампель/Валлис|Method for production of 2-substituted 5-chloroimidazole-4-carbaldehydes|

JP3501484B2|1992-12-17|2004-03-02|三共株式会社|Biphenyl derivative|

TW240224B|1993-02-15|1995-02-11|Shikoku Kakoki Co Ltd|

US5484939A|1993-03-12|1996-01-16|Lonza Ltd.|2-substituted 5-chlorimidazoles|

EP0614889A1|1993-03-12|1994-09-14|Lonza Ag|Process of preparation of optionally 2-substituted 5-chlorimidazol-4-carbaldehydes|

US5442075A|1993-03-12|1995-08-15|Lonza Ltd.|Process for the production of 2-substituted 5-chlorimidazole-4-carbaldehydes|

DK0614890T3|1993-03-12|1997-10-13|Lonza Ag|Process for preparing optionally 2-substituted 5-chloroimidazoles.|

AU679735B2|1993-04-07|1997-07-10|Nissan Chemical Industries Ltd.|Pyrazole derivative|

CA2135541C|1993-11-15|2006-01-10|Gareth Griffiths|Process for the preparation of 2-substituted 5-chloroimidazole-4-carbaldehydes|

US5395847A|1993-12-02|1995-03-07|Smithkline Beecham Corporation|Imidazolyl-alkenoic acids|

AT247091T|1994-05-20|2003-08-15|Smithkline Beecham Corp|INTERMEDIATE PRODUCTS FOR PRODUCING A PHARMACEUTICALLY ACTIVE CONNECTION|

US5922751A|1994-06-24|1999-07-13|Euro-Celtique, S.A.|Aryl pyrazole compound for inhibiting phosphodiesterase IV and methods of using same|

ES2136782T3|1994-10-27|1999-12-01|Asahi Glass Co Ltd|PROCEDURE FOR PRODUCING QUINOLIN-2-IL-BENZOIC ACID COMPOUNDS.|

CA2175420C|1995-05-17|2007-04-10|Gareth Griffiths|Process for the preparation of optionally 2-substituted 5-chloroimidazole-4-carbaldehydes|

JP4103149B2|1996-01-05|2008-06-18|ロンザリミテッド|Process for producing 2-substituted 5-chloroimidazole-4-carbaldehyde|

JP3890453B2|1996-09-18|2007-03-07|リードケミカル株式会社|Novel 2,4-dioxopyrrolidine and 2,4-dioxotetrahydrofuran derivatives and pharmaceuticals containing the compound as an active ingredient|

IT1295405B1|1997-09-30|1999-05-12|Merck Sharp & Dohme Italia S P|USE OF AN ANGIOTENSIN II RECEPTORAL ANTAGONIST FOR DRUG PREPARATION TO INCREASE THE SURVIVAL RATE OF|

BR9908474A|1998-03-04|2000-12-05|Takeda Chemical Industries Ltd|Extended release preparation, process for producing an extended release preparation, and pharmaceutical composition|

FR2785612A1|1998-11-10|2000-05-12|Hoechst Marion Roussel Inc|NOVEL DERIVATIVES OF ERYTHROMYCIN, PROCESS FOR PREPARING THEM AND THEIR APPLICATION AS MEDICAMENTS|

US7812044B2|2001-11-13|2010-10-12|Takeda Pharmaceutical Company Limited|Anticancer agents|

AT321039T|2002-04-29|2006-04-15|Teva Pharma|METHOD FOR PRODUCING LOSARTAN AND LOSARTAN CALIUM SALT|

DE10306179A1|2003-02-13|2004-08-26|Boehringer Ingelheim Pharma Gmbh & Co. Kg|Composition useful for preventing stroke comprises dipyridamole or its salt, acetyl salicylic acid and an angiotensin II antagonist|

DE10335027A1|2003-07-31|2005-02-17|Boehringer Ingelheim Pharma Gmbh & Co. Kg|Use of telmisartan and simvastatin for treatment or prophylaxis of cardiovascular, cardiopulmonary and renal diseases e.g. hypertension combined with hyperlipidemia or atherosclerosis|

SI1844019T1|2005-02-03|2010-01-29|Ratiopharm Gmbh|Methode for the production of losartan|

AT485278T|2005-04-15|2010-11-15|Dishman Pharmaceuticals And Ch|PREPARATION OF 2-SUBSTITUTED 4-CHLORO-5-FORMYLIMIDAZOLES BY VILSMEIER RESPONSE OF THE CONDENSATION PRODUCT OF GLYCIN AND AN IMIDOESTER WITH A FORMAMIDE IN THE PRESENCE OF A TRIFLATEDCATALYST|

EP1908469A1|2006-10-06|2008-04-09|Boehringer Ingelheim Vetmedica Gmbh|Angiotensin II receptor antagonist for the treatment of systemic diseases in cats|

EA020466B1|2007-06-04|2014-11-28|Синерджи Фармасьютикалз Инк.|Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders|

US8969514B2|2007-06-04|2015-03-03|Synergy Pharmaceuticals, Inc.|Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases|

US20090299177A1|2008-06-03|2009-12-03|Mallinckrodt Inc.|Risk Stratification of Patients with Chronic Myocardial Infarction|

JP2011522828A|2008-06-04|2011-08-04|シナジーファーマシューティカルズインコーポレイテッド|Guanylate cyclase agonists useful for the treatment of gastrointestinal disorders, inflammation, cancer, and other disorders|

CA2730603C|2008-07-16|2019-09-24|Synergy Pharmaceuticals Inc.|Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders|

US9616097B2|2010-09-15|2017-04-11|Synergy Pharmaceuticals, Inc.|Formulations of guanylate cyclase C agonists and methods of use|

CN102584628B|2011-12-30|2015-04-22|浙江外国语学院|Method for synthesizing N-carboxymethyl pentamidine|

EP2968439A2|2013-03-15|2016-01-20|Synergy Pharmaceuticals Inc.|Compositions useful for the treatment of gastrointestinal disorders|

EP2970384A1|2013-03-15|2016-01-20|Synergy Pharmaceuticals Inc.|Agonists of guanylate cyclase and their uses|

EA201592263A1|2013-06-05|2016-05-31|Синерджи Фармасьютикалз, Инк.|ULTRASCULAR AGONISTS OF GUANYLACYCLASE C, METHOD OF THEIR RECEIVING AND USING|

US10905676B2|2017-07-07|2021-02-02|Boehringer Ingelheim Vetmedica Gmbh|Angiotensin II receptor antagonist for the prevention or treatment of systemic diseases in cats|

法律状态:

优先权:

申请号 | 申请日 | 专利标题

JP54146728A|JPS6364428B2|1979-11-12|1979-11-12|

[返回顶部]